SCHEMBL1384763

SCHEMBL1384763

Cn1cc2cc(-c3ccnc(S(C)(=O)=O)n3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.42
MAPK9 P45984 2/20 0.42
CSNK1A1 P48729 2/20 0.42
EGFR P00533 1/20 0.42
FRK P42685 1/20 0.42
CSNK1D P48730 10/20 0.40
CSNK1E P49674 7/20 0.40
PTGS2 P35354 7/20 0.39
MAPK14 Q16539 5/20 0.39
MAPK11 Q15759 4/20 0.39
KDM4E B2RXH2 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
STAT3 P40763 1/20 0.39
STAT1 P42224 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TLR9 Q9NR96 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652671 0.87 PTGS2 (0.38) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL1385111 0.86 PTGS2 (0.42) CSNK1DCSNK1EPTGS2MAPK14MAPK11
SCHEMBL1386435 0.85 PTGS2 (0.40) MAP4K4MAPK9CSNK1A1CSNK1DCSNK1E
SCHEMBL31213167 0.82 PTGS2 (0.42) PTGS2MAPK14KDM4EMITFALDH1A1
SCHEMBL1384219 0.81 MAPK14 (0.48) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL2927966 0.79 PTGS2 (0.39) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL29652643 0.77 MAPK14 (0.47) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL2927863 0.77 DYRK1A (0.41) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL1386511 0.77 BRAF (0.46) MAP4K4MAPK9CSNK1A1EGFRFRK
SCHEMBL1554769 0.76 BRAF (0.46) MAP4K4MAPK9CSNK1A1EGFRFRK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAP4K4 24/4885MAPK9 33/4885CSNK1A1 80/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAP4K4 32/4885MAPK9 29/4885CSNK1A1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.